Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander T Cohen

Showing results (81-90 of 227) with videos related to

Pageof 23
Sort By:
Circulation|August 4, 2004
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsAlain Leizorovicz, Alexander T Cohen, Alexander G G Turpie, et al.
Current Medical Research and Opinion|February 9, 2024
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal diseaseAlexander T Cohen, Virginia Noxon, Amol D Dhamane, et al.
Journal of Thrombosis and Haemostasis : JTH|June 18, 2026
A novel dynamic risk score to predict venous thromboembolism recurrences after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancerAlexander T Cohen, Satarupa Choudhuri, Imran Khan, et al.
Journal of Thrombosis and Haemostasis : JTH|June 18, 2026
A novel dynamic risk score to predict clinically significant bleeding after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancerSatarupa Choudhuri, Alexander T Cohen, Imran Khan, et al.
The New England Journal of Medicine|March 29, 2002
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerDavid Bergqvist, Giancarlo Agnelli, Alexander T Cohen, et al.
Clinical Therapeutics|December 28, 2002
Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United StatesMarc F Botteman, Joseph Caprini, Jennifer M Stephens, et al.
Thrombosis and Haemostasis|January 17, 2019
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY TrialAlexander T Cohen, Giancarlo Agnelli, Harry R Buller, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|February 14, 2015
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studiesPaolo Prandoni, Martin H Prins, Alexander T Cohen, et al.
Thrombosis and Haemostasis|August 29, 2018
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonistsSuzanne M Bleker, Marjolein P A Brekelmans, Elise S Eerenberg, et al.
Archives of Internal Medicine|February 16, 2005
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialNils Kucher, Alain Leizorovicz, Paul T Vaitkus, et al.
Pageof 23

Showing results (81-90 of 227) with videos related to

Sort By:
Pageof 23
Circulation|August 4, 2004
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsAlain Leizorovicz, Alexander T Cohen, Alexander G G Turpie, et al.
Current Medical Research and Opinion|February 9, 2024
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal diseaseAlexander T Cohen, Virginia Noxon, Amol D Dhamane, et al.
Journal of Thrombosis and Haemostasis : JTH|June 18, 2026
A novel dynamic risk score to predict venous thromboembolism recurrences after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancerAlexander T Cohen, Satarupa Choudhuri, Imran Khan, et al.
Journal of Thrombosis and Haemostasis : JTH|June 18, 2026
A novel dynamic risk score to predict clinically significant bleeding after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancerSatarupa Choudhuri, Alexander T Cohen, Imran Khan, et al.
The New England Journal of Medicine|March 29, 2002
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerDavid Bergqvist, Giancarlo Agnelli, Alexander T Cohen, et al.
Clinical Therapeutics|December 28, 2002
Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United StatesMarc F Botteman, Joseph Caprini, Jennifer M Stephens, et al.
Thrombosis and Haemostasis|January 17, 2019
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY TrialAlexander T Cohen, Giancarlo Agnelli, Harry R Buller, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|February 14, 2015
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studiesPaolo Prandoni, Martin H Prins, Alexander T Cohen, et al.
Thrombosis and Haemostasis|August 29, 2018
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonistsSuzanne M Bleker, Marjolein P A Brekelmans, Elise S Eerenberg, et al.
Archives of Internal Medicine|February 16, 2005
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialNils Kucher, Alain Leizorovicz, Paul T Vaitkus, et al.
Pageof 23